UNSPSC 51281676: Telavancin hydrochloride

This classification denotes an antimicrobial solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0701472ZG0. European Medicines Agency schedules Telavancin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35005. Telavancin hydrochloride generally arises in the molecular formula C80H106CL2N11O27P.CLH. The term 'telavancin hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule telavancin hydrochloride under HS 29419000 and SITC 54139. Telavancin hydrochloride bears US NLM identifiers UMLS ID C2730005 and NCI Concept Code C87636. SMILES: As of Q4 2014, TELAVANCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

UNSPSC 51281676 Telavancin hydrochloride is a Commodity code for a specific antibiotic pharmaceutical product, but recent state and local solicitations tagged under this code show minimal alignment with the nominal commodity. The two recent opportunities in the dataset involve piggyback pharmaceutical warehouse contracts and naloxone procurement — neither of which targets telavancin specifically. State and local health departments and county health systems have posted opportunities for broad pharmaceutical supply and emergency medical countermeasures through cooperative purchasing vehicles and competitive bidding, but the actual buying under this code does not reflect a focused market for telavancin hydrochloride as a distinct line item.

Activity appears concentrated in Florida and Illinois, based on the two posted records. The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 (IFB 26482DPHPREPDB53392) for doxycycline hyclate and ciprofloxacin hydrochloride, totaling $2,999,999.11 over the contract term; Seminole County, Florida released an IFB in June 2026 (IFB60459723LAS) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response date. Neither opportunity directly reflects procurement of telavancin hydrochloride. The code shows little relevant recent activity for this specific pharmaceutical commodity at the state and local level.